Name | Type | Posted | Actions |
|---|---|---|---|
health.mil/pandt | LINK | Mar 6, 2026 | |
DoD Formulary Placement of FDA Newly Approved Drugs.pdf | Mar 6, 2026 | ||
Price Appendix FAQ NAD.pdf | Mar 6, 2026 | ||
Price List - Zycubo - Electrolyte-Mineral-Trace Element Replacement - NA.xlsx | XLSX | Mar 6, 2026 | |
Price List - Vybrique - Phosphodiesterase-5 Inhibitors - Erectile Dysfunction.xlsx | XLSX | Mar 6, 2026 | |
Price List - Sdamlo - Calcium Channel Blocking Agents - NA.xlsx | XLSX | Mar 6, 2026 | |
Price List - Pivya -Antibiotics - Beta-lactams.xlsx | XLSX | Mar 6, 2026 | |
Price List - Ontralfy - Skeletal Muscle Relaxants and Combinations - NA.xlsx | XLSX | Mar 6, 2026 | |
Price List - Myqorzo - Cardiovascular Agents Miscellaneous - NA.xlsx | XLSX | Mar 6, 2026 | |
Price List - Cardamyst - Calcium Channel Blocking Agents - NA.xlsx | XLSX | Mar 6, 2026 | |
RFQ HT9402-26-Q-9202 NAD.pdf | Mar 6, 2026 |
Department of War Pharmacy Uniform Formulary Blanket Purchase Agreement/ Uniform Formulary Additional Discount Program
Contact and place of performance
Julianne Canaley
San Antonio, TX 78230
USA
The Department of War (DoW) is required by law (10 U.S.C. § 1074g) to establish an effective, efficient, integrated pharmacy benefits program for the Military Health System (MHS) which includes the purchase pharmaceutical agents. The law and implementing regulation (32 CFR Section 199.21) describe the process by which the DoW Pharmacy and Therapeutics (P&T) Committee will consider the relative clinical effec...
View morea. Cardamyst - Calcium Channel Blocking Agents - NA
b. Myqorzo - Cardiovascular Agents Miscellaneous - NA
c. Ontralfy - Skeletal Muscle Relaxants and Combinations - NA
d. Pivya - Antibiotics - Beta-lactams
e. Sdamlo - Calcium Channel Blocking Agents - NA
f. Vybrique - Phosphodiesterase-5 Inhibitors - Erectile Dysfunction
g. Zycubo - Electrolyte-Mineral-Trace Element Replacement - NA
The RFQ, including UF BPA and UF ADP appendices are attached here in. The instructions, important deadlines, and points of contact are in document, RFQ HT9402-26-Q-9202.
Pre-quotation teleconference is on March 11, 2026. Details are stated in Part 2.4. Pre-Quotation Teleconference. Responses to the clinical questions in Part 3.4 shall be submitted via e-mail to the RFQ POC in Part 2.3.1., no later than the date stated in Part 2.3.2.
The Defense Health Agency Aurora, on behalf of the TRICARE Management Activity, has issued solicitation HT9402-26-Q-9202 to support the Department of War (DoW) Pharmacy Uniform Formulary. Pursuant to 10 U.S.C. § 1074g, the agency is establishing an integrated pharmacy benefits program for the Military Health System, which requires the procurement of pharmaceutical agents. This process involves the DoW Pharmacy and Therapeutics (P&T) Committee evaluating the clinical and cost-effectiveness of various drug classes to determine their placement as generic, formulary, Basic Core Formulary, Extended Core Formulary, or non-formulary agents. The government intends to award Uniform Formulary Blanket Purchase Agreements (UF BPA) and Uniform Formulary Additional Discount Program Agreements (UF ADP) based on these clinical decisions.
The scope of this solicitation covers specific drug classes and newly approved drugs scheduled for review during the May 2026 P&T Committee meeting, including Cardamyst, Myqorzo, Ontralfy, Pivya, Sdamlo, Vybrique, and Zycubo. These agents span several categories such as calcium channel blocking agents, cardiovascular agents, skeletal muscle relaxants, beta-lactam antibiotics, phosphodiesterase-5 inhibitors, and electrolyte-mineral-trace element replacements. The primary place of performance is San Antonio, Texas. This requirement is identified under NAICS 325412 for Pharmaceutical Preparation Manufacturing and PSC 6505 for Drugs and Biologicals.
Submissions are due by March 26, 2026. The procurement process includes a pre-quotation teleconference held on March 11, 2026, and requires the submission of clinical responses via email to the designated point of contact, Julianne Canaley. The solicitation is supported by 11 attachments, which include the Request for Quotation (RFQ), pricing appendices, frequently asked questions, and specific price lists for the pharmaceutical agents under review. Details regarding the UF BPA and UF ADP terms are included within the RFQ and its associated appendices.
Generated by Lumen AI
Scoped analysis and attachments—go beyond the summary when you need detail from the solicitation package.